首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist
【2h】

Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist

机译:可卡因的奖励因受体型蛋白酪氨酸磷酸酶D(PTPRD)的表达降低和新型PTPRD拮抗剂而降低

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Receptor-type protein tyrosine phosphatase D (PTPRD) is a neuronal cell-adhesion molecule/synaptic specifier that has been implicated in addiction vulnerability and stimulant reward by human genomewide association and mouse cocaine-conditioned place-preference data. However, there have been no reports of effects of reduced expression on cocaine self-administration. There have been no reports of PTPRD targeting by any small molecule. There are no data about behavioral effects of any PTPRD ligand. We now report (i) robust effects of heterozygous PTPRD KO on cocaine self-administration (These data substantially extend prior conditioned place-preference data and add to the rationale for PTPRD as a target for addiction therapeutics.); (ii) identification of 7-butoxy illudalic acid analog (7-BIA) as a small molecule that targets PTPRD and inhibits its phosphatase with some specificity; (iii) lack of toxicity when 7-BIA is administered to mice acutely or with repeated dosing; (iv) reduced cocaine-conditioned place preference when 7-BIA is administered before conditioning sessions; and (v) reductions in well-established cocaine self-administration when 7-BIA is administered before a session (in WT, not PTPRD heterozygous KOs). These results add to support for PTPRD as a target for medications to combat cocaine use disorders. 7-BIA provides a lead compound for addiction therapeutics.
机译:受体型蛋白酪氨酸磷酸酶D(PTPRD)是一种神经元细胞粘附分子/突触指定物,已通过人类全基因组关联和小鼠可卡因条件的位置偏好数据与成瘾易感性和刺激性奖励有关。然而,没有关于减少表达对可卡因自我给药的影响的报道。没有任何小分子靶向PTPRD的报道。没有有关任何PTPRD配体的行为影响的数据。我们现在报告(i)杂合PTPRD KO对可卡因自我给药的强大作用(这些数据大大扩展了先前的条件化位置偏好数据,并增加了PTPRD作为成瘾疗法目标的原理)。 (ii)将7-丁氧基乙二酸类似物(7-BIA)鉴定为靶向PTPRD并以某种特异性抑制其磷酸酶的小分子; (iii)对小鼠急性或反复给药7-BIA时无毒性; (iv)在调理阶段之前服用7-BIA时,降低了可卡因调理位置的偏爱; (v)减少在会议前使用7-BIA时建立的可卡因自我管理的减少(在WT中,而不是PTPRD杂合KO)。这些结果进一步支持了PTPRD作为抗可卡因使用障碍药物的靶标。 7-BIA提供了成瘾疗法的先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号